» Articles » PMID: 35563446

Sulfated Hyaluronan Binds to Heparanase and Blocks Its Enzymatic and Cellular Actions in Carcinoma Cells

Abstract

We examined whether sulfated hyaluronan exerts inhibitory effects on enzymatic and biological actions of heparanase, a sole endo-beta-glucuronidase implicated in cancer malignancy and inflammation. Degradation of heparan sulfate by human and mouse heparanase was inhibited by sulfated hyaluronan. In particular, high-sulfated hyaluronan modified with approximately 2.5 sulfate groups per disaccharide unit effectively inhibited the enzymatic activity at a lower concentration than heparin. Human and mouse heparanase bound to immobilized sulfated hyaluronan. Invasion of heparanase-positive colon-26 cells and 4T1 cells under 3D culture conditions was significantly suppressed in the presence of high-sulfated hyaluronan. Heparanase-induced release of CCL2 from colon-26 cells was suppressed in the presence of sulfated hyaluronan via blocking of cell surface binding and subsequent intracellular NF-κB-dependent signaling. The inhibitory effect of sulfated hyaluronan is likely due to competitive binding to the heparanase molecule, which antagonizes the heparanase-substrate interaction. Fragment molecular orbital calculation revealed a strong binding of sulfated hyaluronan tetrasaccharide to the heparanase molecule based on electrostatic interactions, particularly characterized by interactions of (-1)- and (-2)-positioned sulfated sugar residues with basic amino acid residues composing the heparin-binding domain-1 of heparanase. These results propose a relevance for sulfated hyaluronan in the blocking of heparanase-mediated enzymatic and cellular actions.

Citing Articles

Biomimetic strategies for the deputization of proteoglycan functions.

Rehan I, Elnagar A, Zigo F, Sayed-Ahmed A, Yamada S Front Cell Dev Biol. 2024; 12:1391769.

PMID: 39170918 PMC: 11337302. DOI: 10.3389/fcell.2024.1391769.


Elevated RHAMM as a biomarker for predicting diabetic kidney disease in patients with type 2 diabetes.

Qi B, Lou Y, Zhu Y, Chen Y, Yang S, Meng F Clin Kidney J. 2024; 17(7):sfae196.

PMID: 39050866 PMC: 11267228. DOI: 10.1093/ckj/sfae196.


The Uptake of Heparanase into Mast Cells Is Regulated by Its Enzymatic Activity to Degrade Heparan Sulfate.

Shi J, Onuki Y, Kawanami F, Miyagawa N, Iwasaki F, Tsuda H Int J Mol Sci. 2024; 25(11).

PMID: 38892469 PMC: 11173065. DOI: 10.3390/ijms25116281.

References
1.
Higashi N, Maeda R, Sesoko N, Isono M, Ishikawa S, Tani Y . Chondroitin sulfate E blocks enzymatic action of heparanase and heparanase-induced cellular responses. Biochem Biophys Res Commun. 2019; 520(1):152-158. DOI: 10.1016/j.bbrc.2019.09.126. View

2.
Blich M, Golan A, Arvatz G, Sebbag A, Shafat I, Sabo E . Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler Thromb Vasc Biol. 2012; 33(2):e56-65. PMC: 3548034. DOI: 10.1161/ATVBAHA.112.254961. View

3.
Miao H, Elkin M, Aingorn E, Stein C, Vlodavsky I . Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int J Cancer. 1999; 83(3):424-31. DOI: 10.1002/(sici)1097-0215(19991029)83:3<424::aid-ijc20>3.0.co;2-l. View

4.
Pala D, Rivara S, Mor M, Milazzo F, Roscilli G, Pavoni E . Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase. Glycobiology. 2016; 26(6):640-54. PMC: 4847616. DOI: 10.1093/glycob/cww003. View

5.
Morris A, Wang B, Waern I, Venkatasamy R, Page C, Schmidt E . The role of heparanase in pulmonary cell recruitment in response to an allergic but not non-allergic stimulus. PLoS One. 2015; 10(6):e0127032. PMC: 4454641. DOI: 10.1371/journal.pone.0127032. View